Fluorescence in situ hybridization(FISH) is a widely used cytogenetic method for detecting gene amplification, deletions, and structural alterations in solid tumors. Its single-cell resolution and high specificity make it essential for assessing biomarkers such as HER2 in both clinical practice and translational research. As targeted and immune oncology therapies expand, there is increasing need for validated, scalable FISH assays that provide reliable and reproducible result across sites. Discovery Life Sciences has developed CAP/CLIA-certified, ISO-accredited FISH workflows using FDA-approved and custom probes to evaluate HER2 amplification and additional novel biomarker targets in FFPE tissues.
